Flag of the European Union EU Clinical Trials Register Help

Clinical trials for migraine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    33 result(s) found for: migraine. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-002866-38 Sponsor Protocol Number: FM-BOEM Start Date*: 2018-01-25
    Sponsor Name:IRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO
    Full Title: Pilot study for the evaluation of the efficacy of OnabotulinumtoxinA in high frequency migraine
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004509-30 Sponsor Protocol Number: 012020 Start Date*: 2021-05-13
    Sponsor Name:INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON
    Full Title: A prospective structural, diffusion and connectomics MRI study on migraine patients treated with Fremanezumab
    Medical condition: MIGRAINE
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000279-26 Sponsor Protocol Number: 56536 Start Date*: 2017-03-07
    Sponsor Name:Erasmus MC
    Full Title: Trigeminovascular effects of propranolol in migraine treatment
    Medical condition: Healthy Volunteers (Migraine)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005256-34 Sponsor Protocol Number: 38589 Start Date*: 2012-10-29
    Sponsor Name:Erasmus MC
    Full Title: Sumatriptan non-responders: evaluation of a possible biomarker
    Medical condition: Healthy Volunteers (Migraine)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017041-58 Sponsor Protocol Number: MIGRANYA Start Date*: 2010-03-18
    Sponsor Name:Consorci Sanitari del Maresme
    Full Title: Ensayo clínico exploratorio sobre la eficacia y la seguridad de la osteopatia en el tratamiento preventivo de la migraña
    Medical condition: La migraña es una condición clínica muy prevalente y altamente invalidante que tiene unos importantes costes sociales. Distintos tratamientos farmacológicos han demostrado ser eficaces en la preven...
    Disease: Version SOC Term Classification Code Term Level
    9 10027603 Migraine headaches HLT
    9 10031268 Osteopathy LLT
    9 10036654 Prevention LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003646-33 Sponsor Protocol Number: 20190008 Start Date*: 2020-06-24
    Sponsor Name:Amgen, Inc.
    Full Title: Comprehensive Assessment of Erenumab Efficacy in Subjects With High Frequency Episodic Migraine With at Least 1 Previously Failed Preventive Treatment: a Global, Double-blind, Placebo-controlled Ph...
    Medical condition: High frequency episodic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) PT (Completed) HU (Completed) BG (Completed) CZ (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-005481-30 Sponsor Protocol Number: ADX10059-206 Start Date*: 2009-03-03
    Sponsor Name:Addex Pharma SA
    Full Title: A phase 2B, randomised, double-blind, placebo-controlled, parallel group, dose-ranging, multicentre study to investigate the efficacy, safety and tolerability of the mGluR5 negative allosteric modu...
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027599 Migraine LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Prematurely Ended) FR (Ongoing) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005239-22 Sponsor Protocol Number: BHV3000-404 Start Date*: 2022-06-20
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens
    Medical condition: Acute Migraine (with or without aura)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) AT (Completed) FR (Completed) SE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002825-22 Sponsor Protocol Number: PROPUDO Start Date*: 2011-12-29
    Sponsor Name:Hospital General Universitario de Alicante
    Full Title: Pilot, placebo-controlled, double-blind, randomized, parallel propofol effective in preventing refractory chronic migraine
    Medical condition: Refractory chronic migraine
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003049-40 Sponsor Protocol Number: 20007A Start Date*: 2022-07-22
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study of add-on eptinezumab treatment to brief educational intervention for the preventive treatment of migraine in pati...
    Medical condition: Migraine and medication overuse headache
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    20.0 10029205 - Nervous system disorders 10072720 Medication overuse headache PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) NL (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004497-25 Sponsor Protocol Number: 18898A Start Date*: 2020-10-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study with an extension period to evaluate the efficacy and safety of eptinezumab for the prevention of migraine in pati...
    Medical condition: Migraine in patients with unsuccessful prior preventive treatments
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) DK (Completed) FI (Completed) BE (Completed) PL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) HU (Completed) SE (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001657-42 Sponsor Protocol Number: 19140A Start Date*: 2021-06-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of eptinezumab for the preventive treatment of migraine
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001175-14 Sponsor Protocol Number: BHV3000-406 Start Date*: 2023-04-17
    Sponsor Name:Biohaven Pharmaceuticals, Inc.
    Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
    Medical condition: migraine attacks with or without aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-002654-36 Sponsor Protocol Number: Zomig nasal 5mg/Imigran novum 100mg Start Date*: 2007-10-08
    Sponsor Name:Carl Dahlöf
    Full Title: A randomised prospective open multi-attack study of patient preference and efficacy between zolmitriptan nasal spray 5 mg and sumatriptan RDT 100 mg in the acute treatment of migraine.
    Medical condition: Migraine with and without aura (G 43.0 and G 43.1)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001989-15 Sponsor Protocol Number: TV48125-MH-40142 Start Date*: 2020-03-27
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Followed by an Open-Label Extension to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of...
    Medical condition: Migraine and major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027603 Migraine headaches HLT
    21.1 100000004873 10025453 Major depressive disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FR (Completed) FI (Completed) GR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001176-34 Sponsor Protocol Number: BHV3000-407 Start Date*: 2023-02-20
    Sponsor Name:Pfizer Inc.
    Full Title: BHV3000-407: A Phase 4, Randomized, Doubleblind, Placebo-controlled Study to Evaluate the Efficacy and Tolerability of Rimegepant for the Prevention of Migraine in Adults with a History of Inadequa...
    Medical condition: migraine headaches with or without aura
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IT (Trial now transitioned) FI (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003342-16 Sponsor Protocol Number: 20170703 Start Date*: 2019-10-21
    Sponsor Name:Amgen Inc
    Full Title: A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) PL (Completed) PT (Completed) FI (Completed) HU (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001661-17 Sponsor Protocol Number: H8H-MC-LAIJ Start Date*: 2019-04-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    Medical condition: Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) DE (Completed) DK (Completed) CZ (Completed) ES (Completed) AT (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001228-20 Sponsor Protocol Number: CAMG334A2401 Start Date*: 2019-04-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adul...
    Medical condition: Migraine prevention
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) FI (Completed) GB (GB - no longer in EU/EEA) SK (Completed) PT (Completed) GR (Completed) PL (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 12:28:22 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA